Drug Profile
Research programme: thymosin beta 4 sulfoxide derivatives - Grannus
Alternative Names: GBL 101Latest Information Update: 12 Sep 2015
Price :
$50
*
At a glance
- Originator Grannus BioSciences
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory tract disorders
Most Recent Events
- 20 Feb 2007 Preclinical trials in Respiratory tract disorders in United Kingdom (unspecified route)